Efficacy for the Annual Relapse Rate after the Immunosuppressive Therapy in Patients Associated with Anti-AQP4 or Anti-MOG Antibody-Positive Optic Neuritis

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td class="align_left">Initial immunosuppressant drugs</td><td class="align_center">Azathioprine 9 cases mycophenolate mofetil 2 cases</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td class="align_left">Complications</td><td class="align_center">Elevation of liver enzymes 1 case nausea 1 case</td></tr><tr><td class="align_left">Median observation period after the beginning of immunosuppressive therapy, years (first-third quartile)</td><td class="align_center">2.8 (1.6–4.0)</td></tr><tr><td class="align_left">Relapse</td><td class="align_center">ON 1 case, 1 time myelitis 2 cases, 5 times</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td><div>ON: optic neuritis, SD: standard deviation.<br/></div></td></tr></table>

Journal of Ophthalmology

tab2

Table 2

Table 2: Efficacy for the Annual Relapse Rate after the Immunosuppressive Therapy in Patients Associated with Anti-AQP4 or Anti-MOG Antibody-Positive Optic Neuritis 

Table 2 | Efficacy for the Annual Relapse Rate after the Immunosuppressive Therapy in Patients Associated with Anti-AQP4 or Anti-MOG Antibody-Positive Optic Neuritis 